首页> 外文期刊>The patient >A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines
【24h】

A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines

机译:进行一项初步研究,以确定需要进一步改善患者和公众参与药物卫生技术评估的领域

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Patient and public participation in health technology assessment (HTA) of medicines has been cited as an important component of the decisionmaking structure; however, how to actually achieve meaningful involvement is less understood. Objectives: Our objectives were to conduct a pilot study to form the basis of future research and to gain insight into how to practically and meaningfully advance patient and public input in HTAs for medicines. Methods: Semi-structured interviews (n = 13) with informants in Australia (n = 7), Canada (n = 3), and the UK (n = 3) were conducted across agencies and experts (n = 9), as well as patient and advocacy groups (n = 4). Results: This pilot study identified through structured interviews three areas for further consideration. Advancement area 1 indicates that industry could help bring the patient perspective into the HTA process through incorporating patient experiences early in the drug development process and by including qualitative research on patient experiences in HTA dossiers. Advancement area 2 involves recognizing and supporting the role of patient advocacy groups, and making use of their access to the genuine patient perspective and experience of living with the condition in question. Finally, advancement area 3 is the continuous development of HTA systems and processes to better facilitate involvement, increasing transparency and feedback, exploring new options for reaching patients, and focusing on creating an active and informed health consumer. Conclusions: The HTA process is becoming increasingly transparent to patients and the public; however, more effort is required to fully engage patients in the decision-making processes for medicine HTAs. This pilot study identified three key areas for further advancement in this field, and recognized a need for further research in the areas of measuring the impact of patient engagement on decision making in medicine HTAs, as well as the best methods to better prepare patient advocacy groups through HTA education and training. These research recommendations will form the basis of a future study with a larger, more comprehensive sample.
机译:背景:患者和公众参与药物的健康技术评估(HTA)被认为是决策结构的重要组成部分;但是,如何真正实现有意义的参与却鲜为人知。目标:我们的目标是进行一项试点研究,以构成未来研究的基础,并深入了解如何切实有效地促进患者和公众对药品HTA的投入。方法:在澳大利亚(n = 7),加拿大(n = 3)和英国(n = 3)对信息提供者的半结构式访谈(n = 13)也跨机构和专家(n = 9)进行。作为耐心和倡导组(n = 4)。结果:该初步研究通过结构化访谈确定了三个领域,需要进一步考虑。进步领域1表明行业可以通过在药物开发过程的早期纳入患者经验,并通过对HTA档案中患者经验的定性研究,来将患者的观点纳入HTA过程。进步领域2涉及到承认和支持患者倡导团体的作用,并利用他们对患者真正的观点和生活在有关疾病中的经验。最后,进步领域3是HTA系统和流程的不断发展,以更好地促进参与,增加透明度和反馈,探索新的选择以接触患者,并着重于创建活跃且知情的健康消费者。结论:HTA流程对患者和公众越来越透明。但是,需要更多的努力才能使患者充分参与药物HTA的决策过程。这项先导研究确定了该领域需要进一步发展的三个关键领域,并认识到有必要在以下方面进行进一步的研究:衡量患者参与对医学HTA决策的影响,以及更好地准备患者倡导小组的最佳方法通过HTA教育和培训。这些研究建议将以更大,更全面的样本构成未来研究的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号